Primær leverkreft, hepatocellulært karsinom
Primær leverkreft, eller hepatocellulært karsinom, er en av de hyppigste kreftsykdommene på verdensbasis. Vanlige årsaker er hepatitt C, alkoholmisbruk og hemakromatose. I Norge er det ikke en utbredt kreftsykdom.

Sist oppdatert:
31. jan. 2023
Hva er hepatocellulært karsinom?
Hepatocellulært karsinom er en kreftsykdom i leveren. Sykdommen utgår fra leverceller (hepatocytter) og er en aggressiv svulsttype. Det er ingen utbredt kreftsykdom i Norge, men på verdensbasis er den en av de hyppigste. Den rangeres som den 5. hyppigste kreftsykdommen blant voksne menn (7. hyppigst blant kvinner), og det er den nest hyppigste kreftsykdommen man dør av.
Antall nye tilfeller med leverkreft i Norge i 2020 var 245 menn og 132 kvinner, men ikke alle disse krefttilfellene skyldtes hepatocellulært karsinom.
Dette dokumentet er basert på det profesjonelle dokumentet Hepatocellulært karsinom . Referanselisten for dette dokumentet vises nedenfor
- Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379:1245. PubMed
- Schwartz JM, Carithers RL, Sirlin CB. Clinical features and diagnosis of primary hepatocellular carcinoma. UpToDate, last updated Mar 29, 2021. UpToDate
- Cicalese L. Hepatocellular carcinoma. Medscape, last updated May 03, 2017. emedicine.medscape.com
- Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018; 29 (Suppl._4): iv238–iv255. www.esmo.org
- Schwartz JM, Carithers RL. Epidemiology and risk factors for hepatocellular carcinoma. UpToDate, last updated Oct 13, 2020. www.uptodate.com
- Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69. PubMed
- Ryerson AB, Eheman CR, Altekruse SF, et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer 2016; 122:1312. PubMed
- Kreftregisteret. Cancer in Norway 2020. Oslo, 2021: www.kreftregisteret.no.
- Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis. 2007 Feb. 11(1):191-207, x-xi.
- Yatsuji S, Hashimoto E, Tobari M et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009; 24: 248–254. PMID: 19032450 PubMed
- Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73. Journal of the American Medical Association
- Yu NC, Chaudhari V, Raman SS, et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol 2011; 9:161. PubMed
- Crippin JS. Biopsy of suspicious liver nodules: does it change management?. Clin Gastroenterol Hepatol 2006; 4: 361. PubMed
- Abdalla EK, Stuart KE. Overview of treatment approaches for hepatocellular carcinoma. UpToDate, last updated Nov 29, 2021. UpToDate
- Llovet JM, Mazzaferro V, Hilgard P, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90. doi:10.1056/NEJMoa0708857 DOI
- Taefi A, Abrishami A, Nasseri-Moghaddam S, Eghtesad B, Sherman M. Surgical resection versus liver transplant for patients with hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD006935. DOI: 10.1002/14651858.CD006935.pub2. DOI
- Awad T, Thorlund K, Gluud C. Cryotherapy for hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD007611. DOI: 10.1002/14651858.CD007611.pub2. DOI
- Zhong JH, Li LQ, Wu LC. Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No.: CD008713. DOI: 10.1002/14651858.CD008713.pub2. DOI
- Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2011, Issue 3. Art. No.: CD004787. DOI: 10.1002/14651858.CD004787.pub2. DOI
- Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208. PubMed